Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
21 4월 2022 - 10:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for precision oncology, today announced the appointment of James
Azzaro to the newly created position of Vice President of
Diagnostic Sales. This appointment supports the company’s objective
to accelerate expansion into the clinical market.
“We are excited to welcome James to the team as he brings more
than 20 years of successful commercial experience in oncology
molecular diagnostics,” said John West, CEO and co-founder of
Personalis. “James will lead our clinical commercial efforts to
pursue business with health care systems and oncologists in the
United States. His focus will include growing our clinical test
volume as we also work to secure reimbursement for NeXT Dx™ this
year and NeXT Personal™ in 2023.”
Mr. Azzaro previously held clinical oncology commercial
leadership roles, including National Sales Director, with Guardant
Health. Earlier, he held commercial positions of increasing
responsibility, up to Oncology Regional Sales Director, over more
than nine years at Myriad Genetics. Most recently, he served as
Chief Commercial Officer for Predicine, driving revenue targets for
molecular testing across oncology and infectious disease markets.
Mr. Azzaro holds a Bachelor of Science in Business Communications
from New Hampshire College.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale, and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the NeXT Platform, Personalis’ business opportunities, leadership,
plans or expectations, future clinical test volume, potential
reimbursement for Personalis’ NeXT Dx and NeXT Personal tests, or
other future events. Such forward-looking statements involve risks
and uncertainties that could cause actual results to differ
materially from any anticipated results or expectations expressed
or implied by such statements. Factors that could materially affect
actual results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including Personalis’ most
recent reports on Forms 8-K, 10-K and 10-Q, the company’s
registration statement on Form S-3 filed on December 30, 2020, and
the company’s prospectus supplement filed on January 3, 2022, and
include those listed under the caption “Risk Factors.” Personalis
disclaims any obligation to update such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220421005184/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com www.westwicke.com 415-202-5678
Media Contact: Jennifer Temple pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024